Market Intelligence, DNA-Protein Crosslink (DPC) Repair Pathways, and High-Purity Reagents for Oncology and Genomic Instability Research.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for SPRTN drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SPRTN Recombinant Protein (Catalytic Domain / Full Length) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 or E. coli expressed. |
View SPRTN Products |
| Gene Delivery | SPRTN Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and DPC accumulation assays. |
View SPRTN Products |
| Benchmark Ab | Anti-SPRTN Recombinant Antibody Sequence-verified positive control for Western Blot, IHC, and IP. |
View SPRTN Products |
| Validator | SPRTN siRNA Set Target-specific knockdown verification in replication stress models. |
View SPRTN Products |
| Related Target A | TOP1 (DNA Topoisomerase 1) Primary source of covalent DNA-Protein Crosslinks (DPCs) resolved by SPRTN. |
View TOP1 Products |
| Related Target B | VCP/p97 (Valosin Containing Protein) AAA+ ATPase segregase that extracts ubiquitinated proteins upstream of SPRTN cleavage. |
View VCP Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Protease activity assay setup | Highly active recombinant SPRTN catalytic domain proteins with verified sequence integrity. |
| Subfamily and metalloprotease counter screening | Inclusion of catalytic inactive mutants (e.g., SPRTN-E112A) to validate target-specific cleavage. |
| Lack of Controls | High-affinity clinical benchmark antibodies included for assay validation. |
| False Positives | Sequence-specific validated siRNA pools included for target knock-down confirmation. |
Live SPRTN R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for SPRTN therapeutics is intensifying, with major players shifting focus from traditional DNA damage response (DDR) targets to specialized DNA-protein crosslink (DPC) resolution pathways. As first-generation DDR therapies (like PARP inhibitors) face clinical resistance, the next wave of R&D is targeting SPRTN to sensitize cancer cells to chemotherapeutics that induce DPCs, such as topoisomerase inhibitors and formaldehyde-generating agents.
Competitive Modality & Indication Snapshot
Connect market trends to assay needs.
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | DDR-focused Biotechs, Academic Consortia | BRCA-deficient Cancers, Colorectal Cancer | In vitro protease cleavage assays (Requires high-purity active SPRTN protein) |
| PROTAC / Degraders | Targeted Protein Degradation (TPD) Developers | Advanced Solid Tumors, Drug-Resistant Cancers | Ubiquitination and degradation kinetics assays (Requires stable SPRTN cell lines via Lentivirus) |
| Combination Therapies | Oncology Biopharma | SCLC, Triple-Negative Breast Cancer (TNBC) | Synergy screening with TOP1/TOP2 inhibitors (Requires TOP1/TOP2 benchmark proteins) |